Tag: PSA

Did you know over 95% of prostate cancers share the same name—adenocarcinoma? This common cell type is usually slow-growing, but not always. Understanding how it develops, why PSA levels matter, and what early detection can reveal is key to knowing your best treatment options. keep reading

For decades, the gloved-finger exam was a standard part of every man's annual physical. Now the evidence is catching up with what many doctors suspected: the digital rectal exam misses too much and finds too little. With MRI able to view the entire prostate, major guidelines have quietly pushed the old exam to the bottom of the list. keep reading

Deciding on Active Surveillance for prostate cancer isn’t always straightforward. Adding genomic testing to standard factors like PSA, MRI, and biopsy can reveal hidden risks and help ensure the safest, most personalized treatment path. keep reading

Detecting prostate cancer early makes nearly 100% treatment success possible, often with fewer side effects. Routine PSA screening and modern imaging tools help identify cancer while it's still most curable. Skipping annual tests risks missing the critical window for best outcomes. keep reading

Focal therapy matches radical prostatectomy in prostate cancer control while offering fewer side effects and preserving treatment choices if cancer returns. Evidence supports its effectiveness for men with localized disease. keep reading

UPDATE: 11/21/2025 Originally published Mar. 11, 2024 The blog below announced news that before radical prostatectomy (RP), multiparametric MRI findings can predict if a prostate cancer (PCa) patient is at risk of recurrence after RP. Prior to MRI predictions, the CAPRA-S score had become the gold standard for predicting biochemical recurrence risk—but only after the surgery was done. Thus, keep reading

Some men avoid doctor visits and underestimate their risk, but skipping annual check-ups can mean missing early prostate cancer. New advances like MRI can help avoid unnecessary biopsies and find cancer when it's most treatable. keep reading

Emerging research reveals that early PSA after radiation and androgen deprivation therapy can help predict prostate cancer outcomes. Meanwhile, a new genomic test is showing potential for identifying which patients face higher risk of long-term urinary side effects. keep reading

For decades, standard TRUS biopsies relied on 12+ random needles—missing aggressive cancers up to 46% of the time and increasing risks of infection. Today, real-time MRI-guided biopsies use just 2–4 precisely targeted needles, giving doctors clearer answers with fewer side effects. Discover why MRI-guided precision is changing prostate cancer diagnosis. keep reading

Each year, hundreds of thousands of men undergo prostate biopsies triggered by PSA results—many of them unnecessary. New research shows that combining PSA testing with MRI can more accurately identify significant cancers while sparing men from needless biopsies and the harms of overtreatment. keep reading